[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jinzhou Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100555447","a-study-on-the-efficacy-of-androgen-deprivation-therapy-combined-with-anti-pd-1-therapy-in-advanced-lung-cancer-100555447",false,"NCT06512207","A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer","A Clinical Investigation on the Efficacy of Leuprorelin Acetate (Androgen Deprivation Therapy) Combined With Sintilimab (Anti-PD-1) in Advanced Lung Cancer","3.Inclusion Criteria:\n\n1. Male patients aged ≥60 years.\n2. ECOG performance status score of 0 \\~1.\n3. Expected survival time of more than 3 months.\n4. Histologically or cytologically diagnosed advanced lung cancer according to the TNM staging system established by AJCC.\n5. Patients who have not previously received any anti-PD-1 treatment.\n6. Patients with adequate bone marrow function, no significant hepatic, renal, or coagulation dysfunction as per laboratory test criteria.\n7. At least one tumor lesion meeting the following criteria:\n\n   * No prior local treatments such as radiotherapy\n   * Not biopsied during the screening period (if biopsy needed, baseline tumor assessment at least 14 days after the screening biopsy).\n   * Measurable at baseline (longest diameter of the lesion ≥10 mm; For a lymph node, short diameter ≥15 mm).\n   * If only one measurable lesion, no prior local treatments such as radiotherapy.\n8. Ability to understand and voluntarily sign a written informed consent form.\n9. Willingness to follow the study protocol and follow-up examinations.\n\nExclusion Criteria:\n\n* Exclusion of cases that do not meet the inclusion criteria","MALE","60 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies. Anti-tumor synergism has been identified by combining ADT with anti-PD-1 immunotherapy for androgen-independent tumors. This study is to investigate the combination of Leuprorelin ADT and Sintilimab (anti-PD-1) therapy in patients with advanced lung cancer.",[26,27],"NSCLC, Stage III","NSCLC, Stage IV",[29,30,31,32],"Androgen Deprivation Therapy （ADT）","Leuprorelin acetate","NSCLC","PD-1 inhibitor","RECRUITING","2025-09-02",{"date":36,"type":37},"2025-09-09","ACTUAL",{"date":39,"type":37},"2023-12-03",{"date":41,"type":20},"2026-06",{"name":43,"class":44},"Jinzhou Medical University","OTHER",""]